Volv Global’s inTrigue machine learning technology detects incidence of disease earlier than currently possible, by analysing vast amounts of medical data to detect subtle patterns among biomarkers.
This ensures that people on the path to developing diseases can have start their healthcare journey early by receiving early interventions. This improves patient outcomes, reduces healthcare burdens and improves quality of life.
Why early detection matters
Early detection of diseases can significantly alter the course of treatment and improve prognosis. Patients diagnosed early often have better health outcomes, fewer complications, and a higher quality of life. By uncovering patients at the earliest disease stages, we ensure timely medical interventions.
Early treatment, before serious onset of disease, can hinder disease progression and reduce long-term complications for patients.
Clinical trials benefit from a larger patient cohort. Identifying suitable candidates earlier, before conventional treatment, bolsters clinical trial recruitment and leads to more effective trials.
Early diagnosis ensures an optimal patient journey, in which patients receive the right treatments saving years of patient suffering and reducing long-term healthcare costs by prioritising medical resources by need.
Volv Global’s inTrigue powers solutions across stakeholders
Earlier triage of patients into a clinical trial before they are given traditional therapies.
Earlier triage of patients, potentially saving years of incorrect treatment.
Physician support for diagnosis of patients before the development of traditional symptoms.
Find patients before the development of traditional symptoms.
Industry-leading technology at work
inTrigue employs sophisticated AI and machine learning algorithms to sift through vast amounts of medical data, identifying subtle patterns that indicate the early presence of diseases. Our technology surpasses traditional methods, ensuring that no potential patient is overlooked.
What people ask
A: Volv Global’s inTrigue uses advanced AI and machine learning to analyse large-scale medical data, including biomarkers, EHRs, and real-world evidence. It identifies subtle health patterns that signal early disease development—enabling earlier intervention and improved patient outcomes.
A: Early detection helps prevent disease progression, enables timely treatment, and reduces healthcare costs. Volv Global’s technology improves patient quality of life and assists providers in correctly diagnosing more patients before symptoms become severe.
A: Volv Global’s solutions benefit clinical development, medical affairs, HEOR, and commercialisation teams by enabling early patient triage, supporting data-driven trial recruitment, and improving the evidence base for access and reimbursement decisions.
A: inTrigue continuously learns from real-world data and clinical feedback, refining its predictive accuracy over time. This adaptive learning approach ensures high precision and sensitivity, allowing healthcare systems to detect diseases earlier than traditional diagnostics.
A: Volv Global operates under strict GDPR and HIPAA compliance, ensuring all data is anonymised and securely handled. Its AI models follow ethical AI principles, maintaining transparency, fairness, and accountability throughout every prediction process.
Shaping the future today
